Sustained response off therapy after fostamatinib: A chronic refractory ITP case report

Auteri, Giuseppe; Biondo, Mattia; Mazzoni, Camilla; Venturi, Marta; Romagnoli, A; Paglia, Simona; Cavo, Michèle; Vianelli, Nicola; Palandri, Francesca

doi:10.1016/j.heliyon.2023.e13462

Cited by 2 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously noted, the published, real‐world data on fostamatinib are limited. Most of the current real‐world data are in the form of case reports 11–13,15 and focuses on particular aspects of fostamatinib treatment, specifically transitioning from TPO‐RAs, 11 elderly patients, 12 sustained response off treatment 13 and patients with increased thrombotic risk 15 . Despite these differences, the case reports are in general agreement that fostamatinib can be effective in heavily pretreated patients, is well‐tolerated with generally mild to moderate adverse effects and can be a viable alternative in ITP patients with increased thrombotic risk 11–13,15 …”

Section: Discussionmentioning

confidence: 99%

“…15 Despite these differences, the case reports are in general agreement that fostamatinib can be effective in heavily pretreated patients, is well-tolerated with generally mild to moderate adverse effects and can be a viable alternative in ITP patients with increased thrombotic risk. [11][12][13]15 A recently published retrospective study examined the safety, efficacy and cost of fostamatinib (n=51) and three TPO-RAs: romiplostim (n = 127), eltrombopag (n = 87) and avatrombopag (n = 44). 14 This study found that at 6 months responses were similar, the frequency of thromboembolic events was lower and the cost was comparable or lower for fostamatinib than for these TPO-RAs.…”

Section: R E Su Ltsmentioning

confidence: 99%

“…Currently there are few studies presenting real-world data on fostamatinib. [11][12][13][14][15] In this study (the Fostasur Study), the Andalusian Group of Congenital Coagulopathies collected and summarized their experience with fostamatinib in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

“…Studies outside the clinical trial environment are relevant to assess the efficacy and safety of real clinical practice. Currently there are few studies presenting real‐world data on fostamatinib 11–15 . In this study (the Fostasur Study), the Andalusian Group of Congenital Coagulopathies collected and summarized their experience with fostamatinib in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study

Jiménez‐Bárcenas,

García‐Donas‐Gabaldón,

Campos‐Álvarez

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryImmune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second‐line treatment for ITP. Real‐world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy. The median PLT at the initiation of fostamatinib was 15 × 109/L. Common reasons for starting fostamatinib were refractoriness or intolerance to prior therapy, oral medication preference, history of thrombosis and cardiovascular risk. Dosing was individualized based on efficacy and tolerance. After 2 weeks, global response rate was 56.8% (response and complete response). Response rates were 70.5%, 62.5% and 64% at 4 weeks, 12 weeks and at the end of the study respectively. Adverse events were mild, and no patients discontinued as a result. This real‐world study demonstrated a response rate similar to fostamatinib as seen in the pivotal clinical trials while including newly diagnosed patients and allowing for individualized dosing.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: R E Su Ltsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study

Jiménez‐Bárcenas,

García‐Donas‐Gabaldón,

Campos‐Álvarez

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

show abstract

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

González-López,

Bermejo-Vega,

Cardesa-Cabrera

et al. 2024

Blood

View full text Add to dashboard Cite

Fostamatinib, a recently approved syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here 138 ITP patients (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively. The median age of our cohort (55.8% women) was 66 years (interquartile range, IQR, 56-80 years). The median time since ITP diagnosis at fostamatinib initiation was 51 months (IQR, 10-166 months). The median number of therapies prior to fostamatinib initiation was 4 (IQR, 2-5), including eltrombopag (76.1%), romiplostim (57.2%) and intravenous immunoglobulins (IVIG) (44.2%). Fifty-eight patients (42.0%) had signs/symptoms of bleeding in the month prior to treatment initiation. 79.0% of patients responded to fostamatinib with 53.6% complete responses (platelet count > 100 x 109 /L). Eighty-three patients (60.1%) received fostamatinib monotherapy achieving a high response rate (85.4%). The proportion of time in response during the 27-month period examined was 83.3%. The median time to platelet response was 11 days (IQR, 7-21 days). Sixty-seven patients (48.5%) experienced adverse events, mainly grade 1-2, the commonest of which were diarrhea (n = 28) and hypertension (n = 21). One patient had deep venous thrombosis and one patient developed acute myocardial infarction. Fostamatinib was shown to be effective with good safety profile in patients with primary and secondary ITP across a wide age spectrum in this real-world study.

show abstract

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report

Cited by 2 publications

References 18 publications

Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study

Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

Contact Info

Product

Resources

About